From Yahoo Finance: 2025-05-14 11:00:00

Shares of Halozyme Therapeutics (HALO) and Johnson & Johnson (JNJ) dropped after Leerink downgraded them due to CMS draft guidance for 2028 IRA drug price controls. Halozyme could face revenue pressure from Opdivo SC, Darzalex Faspro, and Ocrevus SC. J&J’s Darzalex Faspro sales may be affected. In Tuesday trading, J&J fell nearly 3% to $149.87, while Halozyme plunged 27% to $49.02.



Read more at Yahoo Finance: Halozyme, J&J slide as analyst cuts rating on CMS draft guidance